(function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); skip to primary navigationskip to content
 

Dr Ulrich Müller MD, PhD, Specialist Associate of the Royal College of Psychiatrists

Dr Ulrich Müller, MD, PhD, Specialist Associate of the Royal College of Psychiatrists

Consultant Psychiatrist

Lead Clinician of the CPFT Adult ADHD Service

Honorary Visiting Fellow

Member of the Executive Committee of UKAAN


Office Phone: (3)36969

Biography:

Dr Ulrich Müller is an academic psychiatrist with research and service development activities focussing on attention deficit hyperactivity disorder (ADHD) in adults. He is a consultant psychiatrist with Cambridgeshire & Peterborough NHS Foundation Trust (CPFT) and directs the Adult ADHD Research group. He is the lead clinician for the CPFT Adult ADHD Service (with clinics in Cambridge and Peterborough) and for the Adult Locality team in Huntingdon. He has contributed to service development projects all around the UK and trained a generation of European psychiatrist in the management of ADHD in adults.

Ulrich sits on the executive, training and service development committees of the UK Adult ADHD Network (www.UKAAN.org) and is a regular speaker at national training events and international scientific conferences. He has published more than 130 papers and book chapters with an h-index of 31. Before he arrived in Cambridge in 2003 he was trained in Psychiatry, Psychotherapy, Neurological rehabilitation and Cognitive neuroscience in Germany (Würzburg, Munich and Leipzig). He has an international reputation as adult ADHD expert and cognitive psychopharmacologist. He is a senior clinical collaborator of the Behavioural and Clinical Neuroscience Institute (BCNI), University of Cambridge, where he has contributed to methodological developments in pharmacological neuroimaging and cognitive neuropharmacology.

Departments and Institutes

Psychiatry:
Honorary Visiting Fellow

Research Interests

ADHD in adults

Cognitive neuropharmacology

Keywords

  • psychiatry
  • psychopharmacology
  • neuroimaging
  • dopamine

Key Publications

Magon RP, Latheesh B, Müller U (2015) Specialist community adult ADHD clinics in East Anglia: Service evaluation and audit of NICE guideline recommendations. BJPsych Bulletin 39: 136-140.

Bolea-Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, Heal D, Müller U, Nash J, Santosh P, Sayal K, Sonuga-Barke E, Young SJ; Consensus Group (2014) Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 28: 179-203.

Ioannides K, Chamberlain SR, Müller U (2014) Ostracizing caffeine from the pharmacological arsenal for ADHD – was this a correct decision? A literature review. J Psychopharmacol 28: 830-836.

Morein-Zamir S, Dodds C, van Hartevelt TJ, Schwarzkopf W, Sahakian B, Müller U, Robbins T (2014) Hypoactivation in right inferior frontal cortex is specifically associated with motor response inhibition in adult ADHD. Hum Brain Mapping 10: 5142-5152.

Del Campo N, Fryer TD, Hong YT, Smith R, Brichard L, Acosta-Cabronero J, Chamberlain SR, Tait R, Izquierdo D, Regenthal R, Dowson J, Suckling J, Baron J-C, Aigbirhio FI, Robbins TW, Sahakian BJ, Müller U (2013) A positron tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. Brain 136: 3252-3270.

Müller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian BJ (2013) Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology  64: 490-495.

UK Adult ADHD Network (UKAAN) / Asherson P, Young S, Adamou M, Bolea B, Coghill D, Gudjonsson G, Kustow J, Müller U, Pitts M, Thome J (2013) Handbook for Attention Deficit Hyperactivity Disorder in Adults.London, Springer Healthcare.

Müller U, Asherson P (2012) Addressing common misconceptions about attention deficit hyperactivity disorder in adults. Neuropsychiatry 2: 185-188.

Seixas M, Weiss M, Müller U (2012) Systematic review of national and international guidelines on attention deficit hyperactivity disorder (ADHD). J Psychopharmacol 26: 753-765.

Ersche KD, Bullmore ET, Craig KJ, Shabbir SS, Abbott S, Müller U, Ooi C, Suckling J, Barnes A, Sahakian BJ, Merlo-Pich EV, Robbins TW (2010) Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence. Arch Gen Psychiatry 67: 632-644.

Finke K, Dodds CM, Bublak P, Regenthal R, Baumann F, Manly T, Müller U (2010) Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study. Psychopharmacology 210: 317-329.

Lynall M-E, Bassett DS, Kerwin R, McKenna PJ, Kitzbichler M, Müller U, Bullmore ET (2010) Functional connectivity and brain networks in schizophrenia. J Neurosci 30: 9477-9487. 

Winder-Rhodes SE, Chamberlain SR, Idris MI, Robbins TW, Sahakian B, Müller U (2010) Effects of prazosin and modafinil on cognitive and physiological functions in healthy volunteers. J Psychopharmacol 24: 1649-1657.

Chamberlain SR, Hampshire A, Müller U, Rubia K, del Campo N, Craig K, Regenthal R, Suckling J, Roiser J, Grant JE, Bullmore ET, Robbins TW, Sahakian BJ (2009) Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological fMRI study. Biol Psychiatry 65: 550-555.

Dodds CM, Clark L, Dove A, Baumann F, Regenthal R, Bullmore ET, Robbins TW, Müller U (2009b) Sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. Psychopharmacology 207: 35-45.

Chamberlain SR, Menzies LA, Fineberg NA, Del Campo N, Suckling J, Craig K, Müller U, Robbins TW, Bullmore ET, Sahakian BJ (2008) Gray matter abnormalities in trichotillomania: morphometric magnetic resonance imaging study. Br J Psychiatry 193: 216-221.

Dodds CM, Müller U, Clark L, van Loon A, Cools R, Robbins TW (2008) Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning. J Neurosci 28: 5976-5982.

Barnett JH, Jones PB, Robbins TW, Müller U (2007) Effects of COMT Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sorting Test in schizophrenia and healthy controls. Mol Psychiatry 12: 502-509.

Chamberlain SR, Del Campo N, Dowson J, Müller U, Clark L, Robbins TW, Sahakian BJ (2007a) Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 62: 977-984.

Roiser JP, Müller U, Clark L, Sahakian BJ (2007) The effects of acute tryptophan depletion and serotonin transporter polymorphism on emotional processing in memory and attention. Int J Neuropsychopharmacol 10: 449-461.

Chamberlain SR, Müller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ (2006a) Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311: 861-863.

Chamberlain SR, Müller U, Blackwell AD, Robbins TW, Sahakian BJ (2006b) Noradrenergic modulation of working and emotional memory in humans. Psychopharmacology 188: 397-407.

Müller U, Czymmek J, Thöne-Otto A, von Cramon DY (2006a) Reduced daytime activity in patients with acquired brain-damage and apathy: a study with ambulatory actigraphy. Brain Inj 20: 157-160.

Müller U, Fletcher P, Steinberg H (2006b) The origin of pharmacopsychology: Emil Kraepelin's experiments in Leipzig, Dorpat and Heidelberg (1882-1892). Psychopharmacology 184: 131-138.

Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, Sabri O, Stengler-Wenzke K (2005b) Serotonin and dopamine transporter imaging in patients with obsessive compulsive disorder. Psychiatry Res Neuroimag 140: 63-72.

Müller U, Clark L, Lam ML, Moore RM, Murphy CL, Richmond NK, Sandhu RS, Wilkins I, Menon DK, Sahakian BJ, Robbins TW (2005) Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology 182: 205-213.

Hesse S, Barthel H, Schwarz J, Sabri O, Müller U (2004) Advances in in-vivo imaging of serotonergic neurons in neuropsychiatric disorder. Neurosci Biobehav Rev 28: 547-563 (Corrigendum in Neurosci Biobehav Rev 2005, 29: 1119).

Müller U, Steffenhagen N, Regenthal R, Bublak P (2004a) Effects of modafinil on working memory processes in humans. Psychopharmacology 177: 161-169.

Müller U, Wolf H, Kiefer M, Gertz HJ (2003) A systematic comparison of national and international dementia guidelines [in German]. Fortschr Neurol Psychiatr 71: 285-295.

Murai T, Barthel H, Berrouschot J, Sorger D, von Cramon DY, Müller U (2003) Neuroimaging of serotonin transporters in post-stroke pathological crying. Psychiatry Res Neuroimag 123: 207-211. 

Bublak P, Müller U, Grön G, Reuter M, von Cramon DY (2002) Difficult manipulation of working memory information is impaired in Parkinson's disease and related to working memory capacity. Neuropsychology 16: 577-590.

Müller U (2001) Pharmacological treatment of emotional disturbances in patients with acquired brain injury [in German]. Z Neuropsychol 12: 336-349.

Murai T, Müller U, Werheid K, Sorger D, Reuter M, Becker T, von Cramon DY, Barthel H (2001) In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci 13: 222-228.

Müller U, Wächter T, Barthel H, Reuter M, von Cramon DY (2000) Striatal [123I]β-CIT SPECT and prefrontal memory functions in Parkinson's disease. J Neural Transm 107: 303-319.

Ullsperger M, Mecklinger A, Müller U (2000) An electrophysiological test of directed forgetting: the role of retrieval inhibition. J Cogn Neurosci 12: 924-920.

Müller U, von Cramon DY, Pollmann S (1998) D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 18: 2720-2728.